MedTrace Logo

Improving Ventilatory Capacity in Those With Chronic High Level SCI

NCT05041322 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-09-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

Buspirone

Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.

DRUG

Placebo

Subjects take placebo pills (twice a day) for 14 Days.

Sponsors & Collaborators

  • Spaulding Rehabilitation Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-29
Primary Completion
2024-11-01
Completion
2024-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05041322 on ClinicalTrials.gov